Securing the driving force for future growth through active R&D
Securing a globally recognized back-up pipeline
![]() |
CU02 | Nonalcoholic steatohepatitis(NASH) treatment |
![]() |
Obesity treatment through remodeling of adipocytes |
A new concept for NASH treatment using TPH1 inhibitors that do not penetrate the blood brain barrier (BBB).![]() |
|
![]() |
Expanded indication to IBD treatment (inflammatory bowel disease) – Ulcerative colitis, Crohn’s disease |
![]() |
Capable of being designated an orphan drug (Carcinoid cancer, PAH) |
![]() |
CU04 | Cancer (c-Myc inhibitor) |
![]() |
Low-molecular-weight c-myc inhibitor |
Developed a first-in-class bromodomain drug with a new mechanism of action for inhibiting selective and indirect c-myc transcription ![]() |
|
![]() |
Low-molecular compound who are resistant to existing targeted anticancer agents |
![]() |
Prolongs survival rates of patient with cancer (PD-L1 > 1% expression level) by using the combination with immune-oncology drug (lung cancer) |
![]() |
Less toxic to normal cells compared to existing colorectal cancer |
![]() |
Can expand Indications to various cancer types (prostate, colorectal, lung cancer) |
![]() |
CU05 | Cancer (Amigo2-PDK1 inhibitor) |
![]() |
Low-molecular-weight, orally administered cancer treatment |
Developed a first-in-class AKT pathway with a new mechanism of action for inhibiting the combination of the AMIGO2-PDK1 PH domain![]() |
|
![]() |
Expected to show efficacy against advanced lung cancer |
![]() |
Prolongs patient survival by significantly increasing expression level in tissues of cancer patients in proximal inflammation stage when the survival rate decreases |
![]() |
Less toxic to normal cells compared to existing lung cancer treatment |
![]() |
Indication can be expanded to treatment of breast, pancreatic cancer |